Institutional Member Clinical Trials:

• NRG-GI012. https://clinicaltrials.gov/study/NCT07166406

  Hepatocellular Cancer – Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in HCC with Macrovascular Invasion (HELIO-RT)

  This phase III trial evaluates whether adding SBRT to immunotherapy-based systemic treatment in 1st line improves outcomes in patients with advanced HCC that is high-risk based on microvascular invasion 

  Key Inclusion Criteria (see study protocol for greater detail)

  • Either pathologic or radiologic diagnosis of hepatocellular carcinoma (HCC)  
  • HCC macrovascular invasion, defined as enhancing vascular thrombosis demonstrating arterial enhancement and venous or delayed venous washout on multiphasic MRI and/or CT is required.
  • metastatic disease is allowed
  • 5 or fewer discrete liver tumors
  • Total maximal sum of hepatocellular carcinoma tumors < 20 cm in total summed diameter.
  • no direct primary tumor extension into other organs
  • Child-Pugh A or B7 
  • Age ≥ 18
  • ECOG performance status 0-2
  • Hgb > 8, Platelets >60k, ANC > 1,500
  • TBili <4x ULN, AST/ALT < 6x ULN, CrCl > 30

  For more information or to refer a patient, please contact UC Davis Comprehensive Cancer Center, Office of Clinical Research via email at OCRReferral@health.ucdavis.edu or by phone at 916-382-6970.